Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The IASLC 2022 NACLC is a dynamic meeting with a long tradition and will feature the most up-to-date research, diverse topics of interest, and educational sessions with leading experts.

NACLC 2022

North America Conference on Lung Cancer 2022
23–25 September 2022 | Chicago, IL

NACLC 2022

North America Conference on Lung Cancer 2022
23–25 September 2022 | Chicago, IL
The IASLC 2022 NACLC is a dynamic meeting with a long tradition and will feature the most up-to-date research, diverse topics of interest, and educational sessions with leading experts.
Mechanisms of resistance to KRAS G12C inhibitors 3:17
Mechanisms of resistance to KRAS G12C inhibitors
Biagio Ricciuti • 28 Sep 2022
Personalized therapies for patients with KRAS-mutant lung cancer 7:46
Personalized therapies for patients with KRAS-mutant lung cancer
Biagio Ricciuti • 28 Sep 2022
Differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy 2:31
Differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy
Ryan Gentzler • 29 Sep 2022
Considerations for duration and de-escalation of immunotherapy in lung cancer 2:54
Considerations for duration and de-escalation of immunotherapy in lung cancer
Ryan Gentzler • 29 Sep 2022
Unanswered questions in treating NSCLC with radiotherapy 2:27
Unanswered questions in treating NSCLC with radiotherapy
Puneeth Iyengar • 27 Sep 2022
The emerging role of localized therapy in metastatic NSCLC 1:33
The emerging role of localized therapy in metastatic NSCLC
Puneeth Iyengar • 27 Sep 2022
Advances in EFGR-mutant NSCLC treatment 4:37
Advances in EFGR-mutant NSCLC treatment
Biagio Ricciuti • 28 Sep 2022
Tumor mutation burden as a biomarker in NSCLC 4:12
Tumor mutation burden as a biomarker in NSCLC
Biagio Ricciuti • 28 Sep 2022
HCRN LUN13-175: long term survival of carboplatin, nab-paclitaxel and pembrolizumab in NSCLC 2:28
HCRN LUN13-175: long term survival of carboplatin, nab-paclitaxel and pembrolizumab in NSCLC
Ryan Gentzler • 29 Sep 2022
Observing lung cancer progression with liquid biopsies 6:58
Observing lung cancer progression with liquid biopsies
Christian Rolfo • 29 Sep 2022
Optimizing liquid biopsies for early detection in lung cancer 1:41
Optimizing liquid biopsies for early detection in lung cancer
Christian Rolfo • 29 Sep 2022
Optimizing outcomes in patients with cancer cachexia 2:37
Optimizing outcomes in patients with cancer cachexia
Puneeth Iyengar • 27 Sep 2022
Highlights at NACLC 2022: biomarkers in lung cancer and immunotherapy 0:48
Highlights at NACLC 2022: biomarkers in lung cancer and immunotherapy
Christian Rolfo • 29 Sep 2022
Key themes in lung cancer at NACLC 2022 1:32
Key themes in lung cancer at NACLC 2022
Puneeth Iyengar • 27 Sep 2022
The content of VJOncology is intended for healthcare professionals